Comparative Accuracy of Four Guidelines to Predict High-grade Dysplasia or Malignancy in Surgically Resected Pancreatic Intraductal Papillary Mucinous Neoplasms: Small Nuances Between Guidelines Lead to Vastly Different Results

Overview

Journal Ann Hepatobiliary Pancreat Surg

Date 2024 Jun 20

PMID 38898569

Authors

Irene C Perez

Andrew Bigelow

Vanessa M Shami

Bryan G Sauer

Andrew Y Wang

Daniel S Strand

Alexander J Podboy

Todd W Bauer

Victor M Zaydfudim

Allan Tsung

Ross C D Buerlein

Affiliations

Soon will be listed here.

Abstract

Backgrounds/aims: The guidelines regarding the management of intraductal papillary mucinous neoplasms (IPMNs) all have slightly different surgical indications for high-risk lesions. We aim to retrospectively compare the accuracy of four guidelines in recommending surgery for high-risk IPMNs, and assess the accuracy of elevated CA-19-9 levels and imaging characteristics of IPMNs considered high-risk in predicting malignancy or high-grade dysplasia (HGD).

Methods: The final histopathological diagnosis of surgically resected high-risk IPMNs during 2013-2020 were compared to preoperative surgical indications, as enumerated in four guidelines: the 2015 American Gastroenterological Association (AGA), 2017 International Consensus, 2018 European Study Group, and 2018 American College of Gastroenterology (ACG). Surgery was considered "justified" if histopathology of the surgical specimen showed HGD/malignancy, or there was postoperative symptomatic improvement.

Results: Surgery was postoperatively justified in 26/65 (40.0%) cases. All IPMNs with HGD/malignancy were detected by the 2018 ACG and the combined (absolute and relative criteria) 2018 European guidelines. The combined ("high-risk stigmata" and "worrisome features") 2017 International guideline missed 1/19 (5.3%) IPMNs with HGD/malignancy. The 2015 AGA guideline missed the most cases (11/19, 57.9%) of IPMNs with HGD/malignancy. We found the features most-associated with HGD/malignancy were pancreatic ductal dilation, and elevated CA-19-9 levels.

Conclusions: Following the 2015 AGA guideline results in the highest rate of missed HGD/malignancy, but the lowest rate of operating on IPMNs without these features; meanwhile, the 2018 ACG and the combined (absolute and relative criteria) 2018 European guidelines result in more operations for IPMNs without HGD/malignancy, but the lowest rates of missed HGD/malignancy in IPMNs.

Citing Articles

Endoscopic techniques for the diagnosis of pancreatic cystic lesions.

Singh S, Chandan S, Vinayek R, Dhar J, Samanta J, Capurso G World J Gastroenterol. 2025; 31(1):101082.

PMID: 39777250 PMC: 11684177. DOI: 10.3748/wjg.v31.i1.101082.

References

Shin S, Han D, Park K, Kim Y, Park J, Kim S . Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg. 2010; 34(4):776-83. DOI: 10.1007/s00268-010-0416-5. View

Park R, Lim G, Wu J, Koh Y, Teo J, Cheow P . Validation of the clinical utility of 4 guidelines in the initial triage of mucinous cystic lesions of the pancreas based on cross-sectional imaging: Experience with 188 surgically-treated patients. Eur J Surg Oncol. 2020; 46(11):2114-2121. DOI: 10.1016/j.ejso.2020.07.027. View

Marchegiani G, Pollini T, Andrianello S, Tomasoni G, Biancotto M, Javed A . Progression vs Cyst Stability of Branch-Duct Intraductal Papillary Mucinous Neoplasms After Observation and Surgery. JAMA Surg. 2021; 156(7):654-661. PMC: 8135059. DOI: 10.1001/jamasurg.2021.1802. View

Vege S, Ziring B, Jain R, Moayyedi P . American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148(4):819-22. DOI: 10.1053/j.gastro.2015.01.015. View

Konda V, Meining A, Jamil L, Giovannini M, Hwang J, Wallace M . A pilot study of in vivo identification of pancreatic cystic neoplasms with needle-based confocal laser endomicroscopy under endosonographic guidance. Endoscopy. 2013; 45(12):1006-13. DOI: 10.1055/s-0033-1344714. View

Scheiman J . Pancreatic Cysts - Part 1: Using the American Gastroenterological Association Guidelines for the Management of Pancreatic Cysts-A Practical Approach. Pancreas. 2017; 46(6):742-744. DOI: 10.1097/MPA.0000000000000832. View

Elta G, Enestvedt B, Sauer B, Lennon A . ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol. 2018; 113(4):464-479. DOI: 10.1038/ajg.2018.14. View

Hsiao C, Yang C, Wu J, Kuo T, Tien Y . Utility of the 2006 Sendai and 2012 Fukuoka guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas: A single-center experience with 138 surgically treated patients. Medicine (Baltimore). 2016; 95(38):e4922. PMC: 5044913. DOI: 10.1097/MD.0000000000004922. View

Watanabe Y, Endo S, Nishihara K, Ueda K, Mine M, Tamiya S . The validity of the surgical indication for intraductal papillary mucinous neoplasm of the pancreas advocated by the 2017 revised International Association of Pancreatology consensus guidelines. Surg Today. 2018; 48(11):1011-1019. DOI: 10.1007/s00595-018-1691-2. View

10.

Crippa S, Fogliati A, Valente R, Sadr-Azodi O, Arnelo U, Capurso G . A tug-of-war in intraductal papillary mucinous neoplasms management: Comparison between 2017 International and 2018 European guidelines. Dig Liver Dis. 2021; 53(8):998-1003. DOI: 10.1016/j.dld.2021.03.009. View

11.

Ridtitid W, DeWitt J, Schmidt C, Roch A, Stuart J, Sherman S . Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes. Gastrointest Endosc. 2016; 84(3):436-45. DOI: 10.1016/j.gie.2016.02.008. View

12.

Buerlein R, Shami V . Management of pancreatic cysts and guidelines: what the gastroenterologist needs to know. Ther Adv Gastrointest Endosc. 2021; 14:26317745211045769. PMC: 8474323. DOI: 10.1177/26317745211045769. View

13.

Paniccia A, Polanco P, Boone B, Wald A, McGrath K, Brand R . Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts. Gastroenterology. 2022; 164(1):117-133.e7. PMC: 9844531. DOI: 10.1053/j.gastro.2022.09.028. View

14.

Feng Y, Chang X, Zhao Y, Wu D, Meng Z, Wu X . A new needle-based confocal laser endomicroscopy pattern of malignant pancreatic mucinous cystic lesions (with video). Endosc Ultrasound. 2020; 10(3):200-206. PMC: 8248307. DOI: 10.4103/eus.eus_35_20. View

15.

Singhi A, Zeh H, Brand R, Nikiforova M, Chennat J, Fasanella K . American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. Gastrointest Endosc. 2015; 83(6):1107-1117.e2. DOI: 10.1016/j.gie.2015.12.009. View

16.

van Huijgevoort N, Hoogenboom S, Lekkerkerker S, Busch O, Del Chiaro M, Fockens P . Diagnostic accuracy of the AGA, IAP, and European guidelines for detecting advanced neoplasia in intraductal papillary mucinous neoplasm/neoplasia. Pancreatology. 2023; 23(3):251-257. DOI: 10.1016/j.pan.2023.01.011. View

17.

Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang J, Levy P, Ohtsuka T . Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017; 17(5):738-753. DOI: 10.1016/j.pan.2017.07.007. View

18.

Hata T, Dal Molin M, Hong S, Tamura K, Suenaga M, Yu J . Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers. Clin Cancer Res. 2017; 23(14):3935-3944. PMC: 5511555. DOI: 10.1158/1078-0432.CCR-16-2244. View

19.

Sharib J, Fonseca A, Swords D, Jaradeh K, Bracci P, Firpo M . Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making?. Surgery. 2018; 164(6):1178-1184. DOI: 10.1016/j.surg.2018.07.014. View

20.

Pagliari D, Saviano A, Serricchio M, Dal Lago A, Brizi M, Lanza F . Uptodate in the assessment and management of intraductal papillary mucinous neoplasms of the pancreas. Eur Rev Med Pharmacol Sci. 2017; 21(12):2858-2874. View